Long-term Use of Spiolto Respimat in Japanese Patients With Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2016-08-01
- Last Posted Date
- 2019-12-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1335
- Registration Number
- NCT02850978
JARDIANCE Regulartory Post Marketing Surveillance in Korean Type 2 Diabetes Mellitus
- First Posted Date
- 2016-07-29
- Last Posted Date
- 2021-05-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 3368
- Registration Number
- NCT02848833
Patient Convenience Study- NIS RELATE
- Conditions
- Atrial Fibrillation
- Interventions
- First Posted Date
- 2016-07-29
- Last Posted Date
- 2019-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1313
- Registration Number
- NCT02849509
- Locations
- 🇰🇷
Pusan National Univ. Hosp, Busan, Korea, Republic of
🇰🇷Sejong General Hospital, Bucheon, Korea, Republic of
🇮🇩Harapan Kita National Cardiovascular Center, Jakarta Barat, Indonesia
Treatment Convenience in Patients Treated With Dabigatran for Stroke Prophylaxis in Atrial Fibrillation (SPAF)
- Conditions
- Atrial Fibrillation
- First Posted Date
- 2016-07-21
- Last Posted Date
- 2019-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 671
- Registration Number
- NCT02839746
CU Programme of Idarucizumab for Japanese Patients
- First Posted Date
- 2016-07-13
- Last Posted Date
- 2018-03-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1
- Registration Number
- NCT02831660
- Locations
- 🇯🇵
Fukuoka Tokushukai Medical Center, Fukuoka, Kasuga, Japan
Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia
- Conditions
- Schizophrenia
- Interventions
- Drug: BI 425809 dose 1Drug: BI 425809 dose 2Drug: BI 425809 dose 4Drug: BI 425809 dose 3Drug: Placebo
- First Posted Date
- 2016-07-13
- Last Posted Date
- 2021-02-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 509
- Registration Number
- NCT02832037
- Locations
- 🇺🇸
North Carolina Psychiatric Research Center, Raleigh, North Carolina, United States
🇺🇸Midwest Clinical Research, Dayton, Ohio, United States
🇬🇧King's College Hospital, London, United Kingdom
Japanese IP-TN Trial
- First Posted Date
- 2016-07-13
- Last Posted Date
- 2018-07-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 80
- Registration Number
- NCT02831569
- Locations
- 🇯🇵
Shinjuku Res. Park Clinic, Tokyo, I.M., Tokyo, Shinjyuku-ku, Japan
🇯🇵Fukuwa Clinic, Tokyo, Chuo-ku, Japan
🇯🇵Tokyo-Eki Center-building Clinic, Tokyo, Chuo-ku, Japan
Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Linagliptin/Metformin Extended Release Compared With Single Tablets
- Conditions
- Healthy
- Interventions
- Drug: High dose FDC Empagliflozin/Linagliptin/Metformin XR, fedDrug: High dose FDC Empagliflozin/Linagliptin/Metformin XR, fastedDrug: Low dose FDC Empagliflozin/Linagliptin/Metformin XR, fed
- First Posted Date
- 2016-07-04
- Last Posted Date
- 2020-03-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 50
- Registration Number
- NCT02821910
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
Empa/Lina FDC Food Effect Study (Japan)
- Conditions
- Healthy
- Interventions
- Drug: empagliflozin/linagliptin FDC
- First Posted Date
- 2016-06-28
- Last Posted Date
- 2018-08-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 22
- Registration Number
- NCT02815644
- Locations
- 🇯🇵
SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku, Japan
Reversal Dabigatran Anticoagulant Effect With Idarucizumab
- First Posted Date
- 2016-06-28
- Last Posted Date
- 2020-04-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1
- Registration Number
- NCT02815670
- Locations
- 🇷🇺
Children Rep.Clin.Hosp of MoH,Cardio Vas.surgery Dept, Kazan, Kazan, Russian Federation
🇷🇺Regional Clin.Hosp.1,Congen.heart defects&child.Cardiol.dept, Tyumen, Russian Federation